Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
IEFA vs XBI: how they differ
IEFA and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
iShares Core MSCI EAFE ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, IEFA and XBI hold 0% of their money in the same securities at the same weight.
| Only in IEFA | Only in XBI |
|---|---|
| ASML HOLDING 2.62% | MODERNA INC 2.87% |
| HSBC HOLDINGS PLC 1.40% | TWIST BIOSCIENCE CORP 1.81% |
| ROCHE PS PAR AG 1.18% | HALOZYME THERAPEUTICS INC 1.47% |
| SHELL PLC 1.09% | NATERA INC 1.46% |
| MITSUBISHI UFJ FINANCIAL GROUP 1.00% | KYMERA THERAPEUTICS INC 1.45% |
| NOVARTIS AG 0.99% | TRAVERE THERAPEUTICS INC 1.40% |
| NESTLE SA 0.97% | ROIVANT SCIENCES LTD 1.39% |
| ASTRAZENECA PLC 0.94% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| IEFA iShares Core MSCI EAFE ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Core MSCI EAFE | SPDR S&P Biotech |
| Total return, 1 year | +18.0% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +0.5 pts | +46.5 pts |
| Expense ratio | 0.07% | 0.35% |
| Already in the S&P 500 | 0.1% | 8.5% |
| Holdings | 1650 | 154 |
IEFA in plain words
IEFA is an index equity fund tracking the Core MSCI EAFE. Over the year to Sep 11, 2026 it returned +18.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.07% a year. By its holdings filed for Sep 10, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 1650 positions, with the top ten at 12.0%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IEFA or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, IEFA returned +18.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IEFA or XBI?
- IEFA charges 0.07% a year and XBI charges 0.35%, so IEFA is cheaper. Fees come from each fund's prospectus.
- How much do IEFA and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of IEFA and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IEFA against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/iefa-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources